U.S. Clinical Trials Market Size, Share & Analysis Report, 2023-2032
The U.S. Clinical Trials market size accounted for USD 23.5 billion in 2022 and is estimated to achieve a market size of USD 41.69 billion by 2032, growing at a CAGR of 5.9% from 2023 to 2032.
Key Pointers:
Report Scope of the U.S. Clinical Trials Market
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 24.89 Billion |
|
Market Size by 2032 |
USD 41.69 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 5.9% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Phase, study design, indication |
|
Key companies profiled |
Parexel International Corp.: IQVIA Holdings Inc.; LabCorp; Thermo Fisher Scientific (Pharmaceutical Product Development); Charles River Laboratory; ICON plc; Wuxi AppTec; Eli Lilly and Company; SGS SA; Novo Nordisk A/S; Clinipace; Syneos Health Inc.; Pfizer Inc. |
The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.
The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry’s growth.
The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.
Regulatory agencies such as the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration, and several other countries have issued guidelines related to the conduct of clinical trials during the outbreak of coronavirus, and are in complete support of incorporating virtual services.
A virtual trial follows a patient-centered approach, allowing for a more conventional trial experience for the participant together with enhanced data collection, increased diversity of patients, and time savings from the perspective of the trial duration.
With the help of this approach, a large population can be considered for the trial, which improves the study, engagement, recruitment, and retention. Virtual trials can remarkably decrease the effort, time, and burden on participants, investigators, and clinical research coordinators. Thus, making it a very effective and efficient approach for the U.S. clinical trials market.
Phase Insights
The phase III segment held the lion’s share of 54.9% in 2022. This is primarily because of the fact that the phase III clinical trials are most crucial as they involve 300 to 3000 participants and have a longer treatment period. Thus, it is the most expensive phase. Although the number of drugs in this phase is relatively low, the complexity associated with this phase is the highest.
The failure rate in this phase is the highest as the sample size and study design require complex dosing at an optimum level. The loss associated with failure is both human and financial and the majority of the failures occur due to non-compliance with safety and efficacy standards. Only one-third of drugs that enter clinical trials make it to phase III trials.
Phase I studies are anticipated to register the fastest CAGR growth of 7.4% during the forecast period. These studies assess the safety of a device or drug and involve the evaluation of the tolerability and pharmacokinetics of molecules. It determines the effect of a device or drug on humans including the way it is absorbed, metabolized, and excreted.
It also examines the side effects of the drug in case of increased dosage levels. The stage includes 20 to 100 healthy volunteers or people with the disease. The high growth of the segment is majorly due to the increasing drug pipeline of pharmaceutical as well as biopharmaceutical companies.
Study Design Insights
The interventional study design segment accounted for the largest market share of 47.4% in 2022. The segment is also anticipated to register the second-fastest growth during the forecast period. Interventional studies are categorized based on the intervention that is to be studied which includes drug or biologic, behavioral, surgical procedure, and devices.
There has been a significant rise in the number of interventional studies carried out over time. The interventional studies comprise 83.4% of total registered studies in the U.S. as of September 2021, out of which the majority of studies are on drug or biologics, followed by behavioral, clinical procedure, and device intervention studies.
The expanded access trials segment is projected to grow at a CAGR of 5.9% during the forecasted period in the U.S. clinical trials market. It would be a prospective approach for patients having a serious disease or condition, which is life-threatening. In this, a patient is allowed to carry out treatment outside of a clinical trial when no satisfactory therapies are available.
The main factor driving the growth of this segment is increasing innovation. For instance, HUTCHMED, in collaboration with Surufatinib, has started an Expanded Access Program (EAP) in the U.S. for Neuroendocrine Tumors for patients having life-threatening conditions that can’t be treated with available medications or clinical trials.
Indication Insights
The oncology segment accounted for the maximum revenue share of 26.2% & is also anticipated to register the fastest CAGR over the forecast period. The increasing prevalence of cancer and the need for effective treatments against various types of cancer is the key factor driving the growth of the segment. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby fueling the market’s growth.
In 2018, there were 1,120 oncology medicines & vaccines in development by America’s biopharmaceutical firms. These include 140 for various types of leukemia, 136 for lymphoma, 132 for lung cancer, 108 for breast cancer & other medicines for ovarian cancer, prostate cancer, colorectal cancer, childhood cancer, and solid tumors.
The autoimmune segment of the U.S. clinical trials market is expected to be the second most lucrative segment with a CAGR of 5.9% in 2022 due to significant growth in the prevalence of the autoimmune disease, owing to the changing lifestyle and aging population. The autoimmune diseases affect one in 15 Americans including 20 million women & 8 million men.
They are among the top 10 causes of death in women & female children in all age groups up to 64 years of age. There has been a notable increase in R&D spending on autoimmune diseases. As per the NIH’s estimate autoimmune costs approximately USD 100 billion a year in medical care.
Some of the prominent players in the U.S. Clinical Trials Market include:
Segments Covered in the Report
This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the U.S. Clinical Trials market.
By Phase
By Study Design
By Indication
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Phase
1.1.2 Study Design
1.1.3 Indication
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 U.S. Clinical Trials Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage for COVID-19
3.3.1 Therapeutics in development: 271
3.3.2 Vaccines in development: 106
3.4 Fast track of clinical trials
3.4.1 FDA initiative- CTAP
3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
3.5 Solidarity clinical trial
3.5.1 Participation in solidarity trials
3.5.2 Solidarity clinical trial for vaccines
3.6 Virtual clinical trials
3.6.1 In-home clinical services:
3.7 COVID-19 pandemic impact on clinical trial activity
3.7.1 Disrupted clinical trials:
3.7.2 Obstacles in clinical trials:
3.8 Market Dynamics
3.8.1 Market Driver Analysis
3.8.1.1 Adoption of new technology in clinical research
3.8.1.2 Shift towards personalized medicine
3.8.1.3 Growing disease variation and prevalence
3.8.1.4 Increasing collaboration in biomedical research
3.8.1.5 Growth in CRO market
3.8.2 Market Restraint Analysis
3.8.2.1 Pricing pressure
3.8.3 Industry Challenges
3.8.3.1 Rising cost of clinical trial
3.9 U.S. Clinical Trials Market Analysis Tools
3.9.1 Porter’s Five Forces Analysis
3.9.2 PESTEL Analysis
3.9.3 Major Deals & Strategic Alliances Analysis
3.9.3.1 Collaboration
3.9.3.2 Expansion
3.9.3.3 Partnership
3.9.3.4 Acquisition
3.9.3.5 Product launch
3.9.3.6 Merger
3.9.3.7 Joint venture
Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis
4.1 U.S. Clinical Trials: Market Share Analysis, 2023 & 2032
4.2 Phase I
4.2.1 Phase I market, 2020 - 2032
4.3 Phase II
4.3.1 Phase II market, 2020 - 2032
4.4 Phase III
4.4.1 Phase III market, 2020 - 2032
4.5 Phase IV
4.5.1 Phase IV market, 2020 - 2032
Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis
5.1 U.S. Clinical Trials: Market Share Analysis, 2023 & 2032
5.2 Interventional Studies
5.2.1 Interventional market, 2020 - 2032
5.3 Observational Studies
5.3.1 Observational studies market, 2020 - 2032
5.4 Expanded Access Studies
5.4.1 Expanded access studies market, 2020 - 2032
Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis
6.1 U.S. Clinical Trials: Market Share Analysis, 2023 & 2032
6.2 Autoimmune/Inflammation
6.2.1 Autoimmune/inflammation market, 2020 - 2032
6.2.2 Rheumatoid Arthritis
6.2.2.1 Rheumatoid arthritis market, 2020 - 2032
6.2.3 Multiple Sclerosis (MS)
6.2.3.1 Multiple sclerosis market, 2020 - 2032
6.2.4 Osteoarthritis
6.2.4.1 Osteoarthritis market, 2020 - 2032
6.2.5 Irritable Bowel Syndrome (IBS)
6.2.5.1 Irritable Bowel Syndrome (IBS) market, 2020 - 2032
6.2.6 Others
6.2.6.1 Others market, 2020 - 2032
6.3 Pain Management
6.3.1 Pain management market, 2020 - 2032
6.3.2 Chronic pain
6.3.2.1 Chronic pain market, 2020 - 2032
6.3.3 Acute pain
6.3.3.1 Acute pain market, 2020 - 2032
6.4 Oncology
6.4.1 Oncology market, 2020 - 2032
6.4.2 Blood cancer
6.4.2.1 Blood cancer market, 2020 - 2032
6.4.3 Solid tumors
6.4.3.1 Solid tumors market, 2020 - 2032
6.4.4 Others
6.4.4.1 Others market, 2020 - 2032
6.5 CNS Conditions
6.5.1 CNS conditions market, 2020 - 2032
6.5.2 Epilepsy
6.5.2.1 Epilepsy market, 2020 - 2032
6.5.3 Parkinson's disease (PD)
6.5.3.1 Parkinson's disease (PD) market, 2020 - 2032
6.5.4 Huntington's disease
6.5.4.1 Huntington's disease market, 2020 - 2032
6.5.5 Stroke
6.5.5.1 Stroke market, 2020 - 2032
6.5.6 Traumatic Brain Injury (TBI)
6.5.6.1 Traumatic Brain Injury (TBI) market, 2020 - 2032
6.5.7 Amyotrophic Lateral Sclerosis (ALS)
6.5.7.1 Amyotrophic Lateral Sclerosis (ALS) market, 2020 - 2032
6.5.8 Muscle Regeneration
6.5.8.1 Muscle Regeneration market, 2020 - 2032
6.5.9 Others
6.5.9.1 Others market, 2020 - 2032
6.6 Diabetes
6.6.1 Diabetes market, 2020 - 2032
6.7 Obesity
6.7.1 Obesity market, 2020 - 2032
6.8 Cardiovascular
6.8.1 Cardiovascular market, 2020 - 2032
6.9 Other Indications
6.9.1 Other indications market, 2020 - 2032
Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis
7.1 U.S. autoimmune/inflammation clinical trials market, by study design, 2020 - 2032
7.1.1 Interventional studies
7.1.1.1 Interventional studies market, 2020 - 2032
7.1.2 Observational Studies
7.1.2.1 Observational studies market, 2020 - 2032
7.1.3 Expanded access
7.1.3.1 Expanded access market, 2020 - 2032
7.2 U.S. pain management clinical trials market, by study design, 2020 - 2032
7.2.1 Interventional studies
7.2.1.1 Interventional studies market, 2020 - 2032
7.2.2 Observational studies
7.2.2.1 Observational studies market, 2020 - 2032
7.2.3 Expanded access
7.2.3.1 Expanded access market, 2020 - 2032
7.3 U.S. Oncology clinical trials market, by study design, 2020 - 2032
7.3.1 Interventional studies
7.3.1.1 Interventional studies market, 2020 - 2032
7.3.2 Observational studies
7.3.2.1 Observational studies market, 2020 - 2032
7.3.3 Expanded access
7.3.3.1 Expanded access market, 2020 - 2032
7.4 U.S. CNS condition clinical trials market, by study design, 2020 - 2032
7.4.1 Interventional studies
7.4.1.1 Interventional studies market, 2020 - 2032
7.4.2 Observational studies
7.4.2.1 Observational studies market, 2020 - 2032
7.4.3 Expanded access
7.4.3.1 Expanded access market, 2020 - 2032
7.5 U.S. diabetes clinical trials market, by study design, 2020 - 2032
7.5.1 Interventional studies
7.5.1.1 Interventional studies market, 2020 - 2032
7.5.2 Observational studies
7.5.2.1 Observational studies market, 2020 - 2032
7.5.3 Expanded access
7.5.3.1 Expanded access market, 2020 - 2032
7.6 U.S. obesity clinical trials market, by study design, 2020 - 2032
7.6.1 Interventional studies
7.6.1.1 Interventional studies market, 2020 - 2032
7.6.2 Observational studies
7.6.2.1 Observational studies market, 2020 - 2032
7.6.3 Expanded access
7.6.3.1 Expanded access market, 2020 - 2032
7.7 U.S. cardiovascular clinical trials market, by study design, 2020 - 2032
7.7.1 Interventional studies
7.7.1.1 Interventional studies market, 2020 - 2032
7.7.2 Observational Studies
7.7.2.1 Observational studies market, 2020 - 2032
7.7.3 Expanded access
7.7.3.1 Expanded access market, 2020 - 2032
7.8 U.S. others clinical trials market, by study design, 2020 - 2032
7.8.1 Interventional studies
7.8.1.1 Interventional studies market, 2020 - 2032
7.8.2 Observational Studies
7.8.2.1 Observational studies market, 2020 - 2032
7.8.3 Expanded access
7.8.3.1 Expanded access market, 2020 - 2032
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 IQVIA Holdings Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategic initiatives
8.1.2 PAREXEL International Corporation
8.1.2.1 Company overview
8.1.2.2 Service benchmarking
8.1.2.3 Strategic initiatives
8.1.3 Thermo Fisher Scientific (Pharmaceutical Product Development)
8.1.3.1 Company overview
8.1.3.2 Service benchmarking
8.1.3.3 Strategic initiatives
8.1.4 Charles River Laboratory
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Service benchmarking
8.1.4.4 Strategic initiatives
8.1.5 ICON plc
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.5.4 Strategic initiatives
8.1.6 LabCorp
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Service benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Syneos Health Inc.
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Service benchmarking
8.1.7.4 Strategic initiatives
8.1.8 SGS SA
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Service benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Wuxi AppTec
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Service benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Eli Lilly and Company
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Service benchmarking
8.1.11 Novo Nordisk A/S
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Service benchmarking
8.1.12 Pfizer Inc.
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Service benchmarking
8.1.12.4 Strategic initiatives
8.1.13 Covance Inc.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Service benchmarking
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers